Andrew N. Schiff, Director at Aclaris Therapeutics, Inc. (ACRS), sold 106,481 shares at $17.06 ($1.8M) on 2022-11-11, disclosed to the SEC on 2022-11-14.
Open-market sale of $1.8M ACRS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.02 | 11,395 | $194K | 10.7% |
| 2 | $17.02 | 11,395 | $194K | 10.7% |
| 3 | $17.06 | 41,160 | $702K | 38.7% |
| 4 | $17.06 | 41,160 | $702K | 38.7% |
| 5 | $17.08 | 1,371 | $23K | 1.3% |
| Total | $17.05 avg | 106,481 |
| $1.8M |
| 100% |
| Filing → |
| ACRS | SELL | 2022-10-11 | $237K | — | Filing → |
| ACRS | SELL | 2022-10-06 | $1.5M | — | Filing → |
| ACRS | SELL | 2022-06-21 | $592K | — | Filing → |